Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 30.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,017,845 shares of the company’s stock after purchasing an additional 236,940 shares during the period. Pictet Asset Management Holding SA’s holdings in Vaxcyte were worth $83,321,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Bank of Montreal Can acquired a new position in Vaxcyte during the 3rd quarter valued at about $3,104,000. The Manufacturers Life Insurance Company raised its holdings in Vaxcyte by 19.2% during the third quarter. The Manufacturers Life Insurance Company now owns 157,024 shares of the company’s stock worth $17,943,000 after purchasing an additional 25,275 shares in the last quarter. MetLife Investment Management LLC lifted its position in Vaxcyte by 7.7% in the third quarter. MetLife Investment Management LLC now owns 67,833 shares of the company’s stock worth $7,751,000 after purchasing an additional 4,866 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Vaxcyte by 4.0% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,311 shares of the company’s stock valued at $2,435,000 after purchasing an additional 826 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Vaxcyte by 38.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 408,274 shares of the company’s stock valued at $46,653,000 after purchasing an additional 112,512 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Price Performance

PCVX stock opened at $69.46 on Friday. The firm has a market capitalization of $8.94 billion, a P/E ratio of -15.10 and a beta of 1.02. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06. The company’s 50 day simple moving average is $80.07 and its 200-day simple moving average is $92.52.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.16) by $0.14. Sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Activity at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,250 shares of company stock valued at $3,840,018. Company insiders own 3.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They set a “buy” rating and a $135.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.